Mawer Investment Management Ltd. cut its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 16.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 361,477 shares of the company's stock after selling 69,769 shares during the period. Mawer Investment Management Ltd.'s holdings in AbbVie were worth $94,559,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. Verus Financial Partners Inc. grew its position in shares of AbbVie by 1.7% in the third quarter. Verus Financial Partners Inc. now owns 2,048 shares of the company's stock valued at $536,000 after purchasing an additional 35 shares during the last quarter. Evergreen Private Wealth LLC increased its stake in shares of AbbVie by 3.3% during the 3rd quarter. Evergreen Private Wealth LLC now owns 1,090 shares of the company's stock worth $285,000 after purchasing an additional 35 shares in the last quarter. Lifelong Wealth Advisors Inc. increased its stake in shares of AbbVie by 2.1% during the 3rd quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company's stock worth $459,000 after purchasing an additional 36 shares in the last quarter. IMG Wealth Management Inc. raised its position in shares of AbbVie by 22.8% during the 3rd quarter. IMG Wealth Management Inc. now owns 194 shares of the company's stock worth $51,000 after purchasing an additional 36 shares during the last quarter. Finally, Foundry Financial Group Inc. raised its position in shares of AbbVie by 4.6% during the 3rd quarter. Foundry Financial Group Inc. now owns 839 shares of the company's stock worth $219,000 after purchasing an additional 37 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.
AbbVie Stock Performance
AbbVie stock traded up $0.73 during trading on Friday, hitting $295.18. The company's stock had a trading volume of 3,259,920 shares, compared to its average volume of 5,279,493. The stock's fifty day moving average is $275.51 and its 200 day moving average is $240.91. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $302.93. The stock has a market capitalization of $521.76 billion, a price-to-earnings ratio of 50.81, a P/E/G ratio of 1.34 and a beta of 0.20.
AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.73 by $0.09. The firm had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company earned $1.86 EPS. On average, research analysts anticipate that AbbVie Inc. will post 13.98 EPS for the current fiscal year.
AbbVie Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be issued a dividend of $1.82 per share. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Friday, January 15th. This is an increase from AbbVie's previous quarterly dividend of $1.73. AbbVie's payout ratio is currently 125.30%.
Wall Street Analyst Weigh In
ABBV has been the topic of a number of recent research reports. Rothschild & Co Redburn upped their target price on AbbVie from $284.00 to $285.00 and gave the company a "buy" rating in a research note on Tuesday, August 4th. Scotiabank raised their price target on AbbVie from $280.00 to $320.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 6th. Guggenheim raised their price target on AbbVie from $288.00 to $322.00 and gave the stock a "buy" rating in a research report on Monday, November 2nd. Canaccord Genuity Group boosted their price target on AbbVie from $290.00 to $338.00 and gave the stock a "buy" rating in a report on Monday, November 2nd. Finally, Morgan Stanley upped their price objective on AbbVie from $310.00 to $346.00 and gave the company an "overweight" rating in a research report on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, AbbVie currently has an average rating of "Moderate Buy" and an average target price of $297.46.
Check Out Our Latest Stock Report on AbbVie
Insider Activity
In related news, EVP Jeffrey Stewart sold 40,619 shares of the firm's stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the sale, the executive vice president directly owned 83,171 shares of the company's stock, valued at approximately $24,419,005.60. This trade represents a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.06% of the company's stock.
AbbVie News Roundup
These are some of the ABBV news items that stood out recently:
About AbbVie
(
Free Report)
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Further Reading
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.